Predicting genotoxicity and carcinogenicity of drugs and chemicals using using OECD QSAR, DEREK Nexus® and TEST
A comparison of in silico prediction of genotoxicity and carcinogenicity of drugs, with the results obtained from curated data in published literature.
How Syngene’s tech transfer approach helped a biotech company fast-track NDA approval for a novel compound to treat infections
Learn how Syngene ensured 100% first-time-right technology transfer for manufacturing limited number of batches of a novel compound to treat infections, including getting NDA approval in less than two years.
How Syngene screened inhibitors of protein-protein interaction in HTS mode for accelerated drug discovery
Learn how Syngene screened 50,000 compounds using high throughput screening against two different transcription factors for accelerated drug discovery.
How Syngene accelerated drug discovery against a protein target using HTS
Learn how Syngene screened a library of 200,000 compounds using high throughput screening for a single protein target for accelerated drug discovery.
Robust and high-yielding platform process for plasmid DNA production
How Syngene scientists developed a platform process for plasmid DNA production with high titers of > 1 g/L upstream with >25% recovery downstream.
Process development and scale-up of highly challenging biomolecules
Three case studies on downstream platform process development for antibody fragments, three broadly neutralizing antibodies (bNAbs) against HIV, and a new class of regenerative implant used for treating a degenerative disease.
Mycoplasma Contamination Detection in Biopharmaceuticals
Presenting impact of Mycoplasma contamination, available testing methods, and why Syngene prefers NAT-based Mycoplasma detection method over other methods.
How Syngene’s ‘first-time right’ process advanced a novel vascular calcification inhibitor API from Lab-scale to Tox-batch manufacturing successfully
Learn how Syngene supported a pharma company in developing and manufacturing lab-scale and later Tox batches of its target molecule through an improved synthesis route. All this while meeting chemical purity requirements of >98%.
Holistic Target Identification and Validation services
Syngene’s Target Identification and Validation services combine data, informatics, and knowledge about biological target assays for holistic target assessment and risk mitigation in drug discovery.
ADME/PK profiling capabilities
Syngene, with its comprehensive suite of DMPK profiling assays, can help you achieve a high rate of success with your clinical candidates across drug modalities.